DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. Combination Therapies : Recognizing the complex nature of obesity, pharmaceutical companies are investigating combination therapies that target multiple pathways involved in appetite regulation, energy expenditure, and metabolic homeostasis.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 98

DrugBank

MARCH 15, 2024

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. billion, Mounjaro's performance is a testament to the booming demand for innovative therapies targeting diabetes and obesity.  With sales soaring to $2.2

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

Drug Target Review

OCTOBER 1, 2024

At the beginning of my career, during my scholarship, I worked for two years at a research institute where I set up a research project focused on the study of metronomic oral therapies for patients with metastatic breast cancer (BC). That paper, of which I was in the authorship, remains a current point of reference for that therapy usage.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

OCTOBER 9, 2021

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52

Disease FDA Therapies Trials 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. 4 The potential impact on patient outcomes that this will enable is colossal, but further advancement must be made to make such therapies truly accessible. The reason for all this attention and investment is clear: significant benefits for patients.

Treatment 105

Treatment Science DNA Doctors 105

PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

Alta Sciences

APRIL 8, 2025

billion by 2030. 43 Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics pmjackson Tue, 04/08/2025 - 15:28 According to the WHO, at least a billion people are currently living with vision impairment from a preventable or treatable source. billion in 2021 to an estimated $68.93

Clinical Trials 52

Clinical Trials Nurses Trials Compliance 52

The Pharma Data

MARCH 2, 2021

The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options. We are committed to becoming a leader in the obesity space and to providing new therapy options to help people with high unmet medical needs.”. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JULY 15, 2021

The collaboration will introduce a more virtual approach to the evaluation of Alzheimer’s prevention therapies. The current annual societal and economic cost of dementia is estimated at $1 trillion, an amount that is expected to double by 2030 unless we find a way to slow the disease 2.

Trials 52

Trials Therapies Clinical Trials Disease 52

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. The role of this type of CRO is pivotal in the drug development process to determine whether a new therapy is well-tolerated in the general population over a longer period of time. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

DrugBank

FEBRUARY 19, 2025

billion by 2030, the sector is witnessing a shift in how drugs are conceived, developed, and tested.  This discovery highlights how AI can uncover new biological insights and enable the development of targeted therapies for diseases with unmet medical needs. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

MARCH 31, 2022

A significant part of these investments will be made for enhanced capacities in biotechnology, further strengthening the company’s cell and gene therapy production as well as in the expansion of its manufacturing site in Berkeley, USA. Germany will remain an important strategic manufacturing location for the company.

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Therapies Production 52

The Pharma Data

NOVEMBER 1, 2020

billion by 2030 2. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies. According to the Multiple Sclerosis International Federation (MSIF), more than 2.8 million people around the world are affected by MS today 1.

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

The Pharma Data

MARCH 9, 2021

Additional data highlight Lilly’s AD program focused on developing both disease-modifying therapies that slow clinical progression by targeting the underlying causes of AD and novel diagnostics and biomarkers to enable a timely and more accurate diagnosis. About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

JULY 29, 2021

Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. In June 2021, Lilly announced the U.S. vice president of pain and neurodegeneration, Lilly.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Novartis is taking bold steps to increase patient reach in LMICs with its strategic innovative therapies by at least 200% by 2025.

Therapies 52

Therapies Regulations Government Disease 52

The Pharma Data

MAY 3, 2021

This includes making COVID-19 therapies available in low- and middle-income countries, as well as hurricane preparedness in the U.S. Lilly ‘s commitment also supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

Vial

APRIL 18, 2024

from 2023 to 2030. billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Specifically, the global ophthalmic clinical trials market, valued at USD 1.5 billion in 2022, anticipates steady growth at a compound annual growth rate (CAGR) of 6.6% Additionally, the ophthalmic drugs market, valued at USD 33.81

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. billion in 2030. How do CROs solve the challenges of managing clinical trials?

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Bayer recently formed its own cell and gene therapy platform as part of its transformation strategy for Pharmaceuticals. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

MARCH 13, 2021

. “A key insight of the results from the TRAILBLAZER-ALZ study is that donanemab not only significantly reduced the amount of amyloid deposition in these patients but also slowed the clinical progression of the disease suggesting that this could be a disease-modifying therapy. Source link:[link].

Disease 40

Disease Trials Treatment Medical Schools 40

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. Certain IVDs will be treated differently; companion diagnostics used with drug therapies would have to include the international non-proprietary name (INN) of the medicine the test is used with. There were myriad reasons for the extension.

Regulations 40

Regulations International Production Government 40

The Pharma Data

JUNE 11, 2025

Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), the company’s oral, pangenotypic direct-acting antiviral (DAA) therapy. If treated early with safe and effective therapies, providers can cure virtually all patients with hepatitis C before it escalates. Global and U.S.

FDA Approval 40

FDA Approval FDA Virus Therapies 40

DrugBank

AUGUST 9, 2024

In 2021, an estimated 537 million adults were living with diabetes, a number projected to reach 643 million by 2030. billion by 2030. These new therapies have demonstrated significant LDL cholesterol reductions, but their high cost remains a barrier to widespread adoption. The market for cardiovascular drugs, valued at 155.6

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

PPD

APRIL 14, 2025

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. However, it is representative of the average across most of todays trials, where only 2030% of participants are women. Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. One example is the acquisition of Asklepios BioPharmaceutical (AskBio), a leading company in the field of gene therapy.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

SEPTEMBER 28, 2020

Developing next-generation therapies. Assessing an innovative therapy for patients with Chagas cardiomyopathy. Further, in 2019, we launched the first clinical study in people with heart failure caused by Chagas disease to assess an innovative therapy in this underserved patient population. Follow us on social media.

Disease 52

Disease Therapies Treatment Clinical Research 52

The Pharma Data

APRIL 24, 2021

In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Follow us on social media at #MalariaFuture. Video of No one should die of malaria. Read the reports. Additional Resources.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

FEBRUARY 24, 2022

– Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction. with more than 8 million cases expected by 2030. . with more than 8 million cases expected by 2030.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

NOVEMBER 11, 2021

By 2030, we aim to impact the lives and health of 50 million people and engage 20,000 Boehringer Ingelheim employees, through supporting social entrepreneurs in vulnerable communities.”. Boehringer Ingelheim Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals.

Vaccine 40

Vaccine Therapies Marketing Research 40

The Pharma Data

FEBRUARY 22, 2021

FDA in 2012 to treat multidrug-resistant TB (MDR-TB) TB in adults, as part of combination therapy, it was the first targeted TB medicine with a novel mechanism of action in more than 40 years. Johnson & Johnson has been a committed partner in the fight against TB for more than two decades. With the goal of saving an estimated 1.8

Government 40

Government Disease Treatment International 40

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. An MAA for HoFH has also been submitted in the EU.

Production 40

Production Trials FDA FDA Approval 40

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. Cirsium Bio is using plants to produce viral vectors for gene therapy. The total global bioprocessing capacity was estimated at 17.4 million liters in 2021, according to an analysis by BioProcess International.

Engineering 87

Engineering Vaccine Production RNA 87